Chengda Bio released its 2026 half-year report, showing net profit attributable to the parent of 33.28 million yuan, down 72.8% year on year. Operating revenue was 677 million yuan, down 4.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 26.83 million yuan, down 73.7% year on year. Net operating cash flow was 70.76 million yuan, down 44.1% year on year. Second-quarter operating revenue was 404 million yuan, up 15.9% year on year, while net profit attributable to the parent was 35.19 million yuan, down 29.7% year on year. The company said sales volume of its human rabies vaccine grew, but a value-added tax policy adjustment led to a slight decline in sales revenue, and net profit was affected by both lower operating revenue and higher costs and expenses.
Liaoning Chengda Biotechnology Co. Ltd. ANet profit attributable to parent fell 72.8% to 33.28 million yuan, with revenue down 4.2% and costs up.
